Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Lucira Health, Inc. (LHDX)

Sector - Healthcare

Price chart

-18.26%
Return from IPO

Company News

IPO Profile

About company

They are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. They have developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. They designed their test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. They believe the novel coronavirus, or COVID-19, pandemic has shown the infectious disease testing infrastructure in the United States was not designed to accommodate the immediate demands of infectious disease control on a mass-population scale. The testing options today are too expensive, inaccurate, or are inaccessible due to slow time to results or complexity. Mass-population infectious disease testing requires a testing platform that can provide accurate and clinically relevant results on-the-spot, be affordably mass produced, portable and easy-to-use anywhere. Their LUCIRA COVID-19 All-In-One Test Kit, or their COVID-19 test kit, is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. They believe, at scale, it will be an affordable, mass-population testing solution. Their initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications.
Industry
In Vitro & In Vivo Diagnostic Substances
CEO CFO
Erik T. Engelson Daniel George
Employees Founded
57 2013

Contacts

Address: 1412 62nd Street Emeryville, California 94608

Telephone: (510) 350-8071

Web page: http://www.lucirahealth.com

IPO information

Expected Date 2/5/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.8
Shares Revised (MM) 9
Expected offer amount (MM) $124.8
Realized offer amount(MM) $153

Financial Data (last reporting year)

Market Cap (MM) $573.92
Revenues (MM) $0.27
Net Income (Loss) (MM) $-22.3

Voting

What do you think will happen with the LHDX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: BofA Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
BofA Securities/ William Blair
CO-Managers
LifeSci Capital

Sector: Healthcare

Tweets about $LHDX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats